secwatch / observer
8-K filed December 8, 2022, 6:59 PM ET ticker EW CIK 0001099800
leadership confidence high sentiment neutral materiality 0.65

Edwards Lifesciences CEO Mike Mussallem retiring May 2023; Bernard Zovighian to become CEO

Edwards Lifesciences Corp

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Larry Wood

Corporate Vice President and Group President
EW · Edwards Lifesciences Corp
Effective
2023-01-01
Filed
December 8, 2022, 6:59 PM ET
the Board’s appointment of Larry Wood to an expanded role as corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical Structural Heart effective January 1, 2023
Appointed

Bernard J. Zovighian

Chief Executive Officer
EW · Edwards Lifesciences Corp
Effective
2023-05-11
Filed
December 8, 2022, 6:59 PM ET
At the 2023 Annual Meeting, Mr. Mussallem will be succeeded as CEO by Bernard J. Zovighian, currently corporate vice president and general manager for Edwards’ Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business.
Appointed

Bernard J. Zovighian

President
EW · Edwards Lifesciences Corp
Effective
2023-01-01
Filed
December 8, 2022, 6:59 PM ET
On December 6, 2022 the Board appointed Bernard J. Zovighian as President of the Company, effective January 1, 2023, until he becomes CEO on May 11, 2023.
Role change

Michael A. Mussallem

Non-executive Chairman
EW · Edwards Lifesciences Corp
Effective
2023-05-11
Successor
Bernard J. Zovighian
Filed
December 8, 2022, 6:59 PM ET
On December 6, 2022, Michael A. Mussallem informed the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), of his decision to retire as Chief Executive Officer of Edwards in connection with Edwards’ Annual Meeting of Stockholders on May 11, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Larry Wood was appointed as Corporate Vice President and Group President at Edwards Lifesciences Corp.

Action
appointed to expanded role
Role
Corporate Vice President and Group President
Exact text from the filing
the Board’s appointment of Larry Wood to an expanded role as corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical Structural Heart effective January 1, 2023
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Bernard J. Zovighian was appointed as Chief Executive Officer at Edwards Lifesciences Corp.

Action
appointed
Role
Chief Executive Officer
Exact text from the filing
At the 2023 Annual Meeting, Mr. Mussallem will be succeeded as CEO by Bernard J. Zovighian, currently corporate vice president and general manager for Edwards’ Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Bernard J. Zovighian was appointed as President at Edwards Lifesciences Corp.

Action
appointed
Role
President
Exact text from the filing
On December 6, 2022 the Board appointed Bernard J. Zovighian as President of the Company, effective January 1, 2023, until he becomes CEO on May 11, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael A. Mussallem retired as Non-executive Chairman at Edwards Lifesciences Corp.

Action
retired
Role
Non-executive Chairman
Exact text from the filing
On December 6, 2022, Michael A. Mussallem informed the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), of his decision to retire as Chief Executive Officer of Edwards in connection with Edwards’ Annual Meeting of Stockholders on May 11, 2023.
View on SEC.gov

Edwards Lifesciences Corp filing history →

Source: SEC EDGAR
accession 0001193125-22-301136
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.